ABCA1 | ATP-binding cassette, sub-family A (ABC1), member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| ![](/images/69889/ihc_selected_60x60.jpg) | ![](/images/57283/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/69889/151524_B_8_1_rna_selected_60x60.jpg) | Expressed in all |
ABCC1 | ATP-binding cassette, sub-family C (CFTR/MRP), member 1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| ![](/images/2380/ihc_selected_60x60.jpg) | | ![](/images/2380/ihc_cell_selected_60x60.jpg) | ![](/images/2380/8487_B_7_5_rna_selected_60x60.jpg) | Expressed in all |
ABCC2 | ATP-binding cassette, sub-family C (CFTR/MRP), member 2 | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/4860/14118_B_8_6_rna_selected_60x60.jpg) | Group enriched |
ABCC8 | ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| ![](/images/42318/ihc_selected_60x60.jpg) | ![](/images/42318/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/11451/26291_B_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
ACE | Angiotensin I converting enzyme | Candidate cardiovascular disease genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images/2426/ihc_cell_selected_60x60.jpg) | ![](/images/2426/6196_B_7_3_rna_selected_60x60.jpg) | Group enriched |
ACE2 | Angiotensin I converting enzyme 2 | Enzymes FDA approved drug targets Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/26174/58083_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
ACHE | Acetylcholinesterase (Yt blood group) | Blood group antigen proteins Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enriched |
ADORA1 | Adenosine A1 receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| ![](/images_static/rna_center.gif) | ![](/images/52157/823_C8_2_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
ADORA2A | Adenosine A2a receptor | Cancer-related genes FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Mixed |
ADORA2B | Adenosine A2b receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
ADORA3 | Adenosine A3 receptor | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| ![](/images/28509/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/28509/61500_B_9_8_rna_selected_60x60.jpg) | Tissue enhanced |
ADRA1A | Adrenoceptor alpha 1A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| ![](/images/29679/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/29678/70371_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
ADRA1B | Adrenoceptor alpha 1B | Cancer-related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
ADRA1D | Adrenoceptor alpha 1D | FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins
| ![](/images/38789/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/38789/80138_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
ADRA2A | Adrenoceptor alpha 2A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Mixed |
ADRA2B | Adrenoceptor alpha 2B | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| ![](/images/66029/154301_B_9_8_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/66029/154298_B_1_4_rna_selected_60x60.jpg) | Mixed |
ADRA2C | Adrenoceptor alpha 2C | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| ![](/images/57688/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images/57688/ihc_cell_selected_60x60.jpg) | ![](/images/57688/133031_B_5_5_rna_selected_60x60.jpg) | Tissue enhanced |
ADRB1 | Adrenoceptor beta 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images/67972/150140_A_4_8_selected_60x60.jpg) | ![](/images/67972/149849_A_9_5_rna_selected_60x60.jpg) | Tissue enhanced |
ADRB2 | Adrenoceptor beta 2, surface | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| ![](/images/3431/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/3431/11305_B_9_4_rna_selected_60x60.jpg) | Mixed |
ADRB3 | Adrenoceptor beta 3 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
AGTR1 | Angiotensin II receptor, type 1 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images/3596/ihc_cell_selected_60x60.jpg) | ![](/images/3596/11016_B_9_3_rna_selected_60x60.jpg) | Group enriched |
ALK | Anaplastic lymphoma receptor tyrosine kinase | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| ![](/images/10694/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/10694/26073_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
ANO1 | Anoctamin 1, calcium activated chloride channel | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| ![](/images/32148/ihc_selected_60x60.jpg) | ![](/images/32148/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/32148/77451_B_9_1_rna_selected_60x60.jpg) | Mixed |
ASIC1 | Acid-sensing (proton-gated) ion channel 1 | FDA approved drug targets Predicted membrane proteins
| ![](/images_static/rna_center.gif) | ![](/images/65870/1233_E9_5_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enriched |
ATP1A1 | ATPase, Na+/K+ transporting, alpha 1 polypeptide | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| ![](/images/18702/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/18702/42623_B_8_6_rna_selected_60x60.jpg) | Expressed in all |
ATP2C1 | ATPase, Ca++ transporting, type 2C, member 1 | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Transporters
| | ![](/images/10207/if_selected_60x60.jpg) | ![](/images/10207/ihc_cell_selected_60x60.jpg) | ![](/images/35116/84725_B_9_5_rna_selected_60x60.jpg) | Expressed in all |
ATP4A | ATPase, H+/K+ exchanging, alpha polypeptide | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/39154/83027_B_9_7_rna_selected_60x60.jpg) | Tissue enriched |
AVPR1A | Arginine vasopressin receptor 1A | FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
AVPR1B | Arginine vasopressin receptor 1B | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| ![](/images/17337/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/17337/111003_B_7_8_rna_selected_60x60.jpg) | Not detected |
AVPR2 | Arginine vasopressin receptor 2 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| ![](/images/46678/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/46678/108998_A_3_1_rna_selected_60x60.jpg) | Mixed |
BCL2 | B-cell CLL/lymphoma 2 | Cancer-related genes Disease related genes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| ![](/images/3/155167_A_4_8_selected_60x60.jpg) | ![](/images_static/na_center.gif) | | ![](/images/3/155162_A_2_3_rna_selected_60x60.jpg) | Expressed in all |
BDKRB2 | Bradykinin receptor B2 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| ![](/images/50841/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/50841/116296_B_9_2_rna_selected_60x60.jpg) | Mixed |
CA14 | Carbonic anhydrase XIV | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| ![](/images/8482/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | | ![](/images/8482/23361_B_8_6_rna_selected_60x60.jpg) | Tissue enhanced |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | ![](/images/17258/ihc_cell_selected_60x60.jpg) | ![](/images/17258/40117_B_9_2_rna_selected_60x60.jpg) | Tissue enhanced |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images/64258/1331_H7_1_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/64258/144292_A_4_3_rna_selected_60x60.jpg) | Tissue enhanced |
CACNA1B | Calcium channel, voltage-dependent, N type, alpha 1B subunit | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| ![](/images/44347/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/44347/97165_B_7_3_rna_selected_60x60.jpg) | Group enriched |
CACNA1C | Calcium channel, voltage-dependent, L type, alpha 1C subunit | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/39796/84042_B_8_3_rna_selected_60x60.jpg) | Tissue enhanced |
CACNA1D | Calcium channel, voltage-dependent, L type, alpha 1D subunit | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| ![](/images/20215/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/20215/47849_B_7_3_rna_selected_60x60.jpg) | Tissue enhanced |
CACNA1F | Calcium channel, voltage-dependent, L type, alpha 1F subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Mixed |
CACNA1G | Calcium channel, voltage-dependent, T type, alpha 1G subunit | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| ![](/images/4714/ihc_selected_60x60.jpg) | ![](/images/4714/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/4714/13325_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
CACNA1H | Calcium channel, voltage-dependent, T type, alpha 1H subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| ![](/images/39125/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/39125/91318_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
CACNA1I | Calcium channel, voltage-dependent, T type, alpha 1I subunit | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
CACNA1S | Calcium channel, voltage-dependent, L type, alpha 1S subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images/56815/ihc_cell_selected_60x60.jpg) | ![](/images/48892/130229_B_8_2_rna_selected_60x60.jpg) | Tissue enriched |
CACNA2D1 | Calcium channel, voltage-dependent, alpha 2/delta subunit 1 | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/8621/24302_B_8_1_rna_selected_60x60.jpg) | Mixed |
CACNG1 | Calcium channel, voltage-dependent, gamma subunit 1 | FDA approved drug targets Predicted membrane proteins Transporters
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enriched |
CALY | Calcyon neuron-specific vesicular protein | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| ![](/images/42283/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/42283/92356_B_8_4_rna_selected_60x60.jpg) | Group enriched |
CAMLG | Calcium modulating ligand | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| ![](/images/52636/ihc_selected_60x60.jpg) | ![](/images/52636/if_selected_60x60.jpg) | ![](/images/52636/ihc_cell_selected_60x60.jpg) | ![](/images/52636/121720_A_3_4_rna_selected_60x60.jpg) | Expressed in all |
CASR | Calcium-sensing receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images/39686/158078_A_4_8_selected_60x60.jpg) | ![](/images/50335/143981_B_7_7_rna_selected_60x60.jpg) | Tissue enhanced |
CCKAR | Cholecystokinin A receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| ![](/images/5619/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/5619/15463_B_8_1_rna_selected_60x60.jpg) | Group enriched |
CCKBR | Cholecystokinin B receptor | Cancer-related genes FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| ![](/images/41976/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/41976/93138_B_4_2_rna_selected_60x60.jpg) | Group enriched |